Asia Pacific Biodefense Market Outlook, 2030

The Asia-Pacific biodefense market is experiencing rapid expansion, fueled by a confluence of factors including increasing public health concerns, rising geopolitical tensions, and the region's burgeoning economic development. This market is characterized by a growing emphasis on preparedness and response capabilities against a spectrum of biological threats, ranging from emerging infectious diseases to potential bioterrorism incidents. The region's diverse landscape, encompassing densely populated urban centers and vast rural areas, necessitates robust biodefense strategies that can address a wide range of challenges. The increasing frequency of disease outbreaks, exemplified by the COVID-19 pandemic, has underscored the vulnerability of Asia-Pacific nations to biological hazards, leading to significant investments in biodefense infrastructure and research. Furthermore, the region's strategic importance and rising geopolitical tensions are driving governments to bolster their biosecurity measures, including the development and stockpiling of vaccines, therapeutics, and detection technologies. Countries like China, India, Japan, and South Korea are at the forefront of this market, investing heavily in research and development, and establishing advanced biodefense facilities. The region's expanding healthcare infrastructure and growing pharmaceutical industry are also contributing to market growth, facilitating the development and production of innovative biodefense solutions. The increasing adoption of advanced technologies, such as genomics, proteomics, and artificial intelligence, is enhancing the capabilities of biothreat detection and response systems across the region. Moreover, the rising awareness of the interconnectedness of human, animal, and environmental health is driving the adoption of a One Health approach, integrating multiple disciplines to address biological threats. The need for enhanced disease surveillance, rapid diagnostics, and effective countermeasures is driving the market. Additionally, the increasing focus on national biosecurity and the protection of critical infrastructure is further propelling market growth. The Asia-Pacific region continues to navigate complex public health challenges and geopolitical uncertainties, the biodefense market is poised for significant expansion, driven by the imperative to safeguard public health and national security.

According to the research report " Asia Pacific Biodefense Market Overview, 2030," published by Bonafide Research, the Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion in the fast-growing region despite the COVID-19 impact. Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies. The growing prevalence of infectious diseases, such as coronavirus, Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the Biodefense Market growth. The growth of the Biodefense Market is driven by factors such as the favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM in the Asia Pacific region. However, low R&D funding by government in developing and underdeveloped economies is likely to restrain the market growth to a certain extent. The growing threat of terrorism, coupled with continually rising tension between nations across the globe, is one of the key factors driving the growth of the market. Furthermore, the increasing defense expenditure by the governments of several nations to improve both internal and external security is also providing a boost to the market growth. In line with this, there is widespread adoption of innovative technologies, such as gene chips, for the detection of pathogens in the fields of nanotechnology, forensics and biodefense-related drug development. Additionally, government agencies are recognizing various chemical, biological, nuclear and radiological threats and are developing medical countermeasures to minimize the adverse effects of these attacks. Apart from this, there is an increasing awareness regarding synthetic biology for improving agricultural yields, which is also creating a positive impact on the market growth. Apart from these, due to the recent COVID-19 pandemic, there has been an increasing demand for medical measures and threat detection procedures, which is also providing a boost to the market growth. Other factors, including extensive research and development (R&D) in the field of biotechnology, along with the availability of advanced biothreat detection devices, are projected to drive the market further. Some major findings of the biodefense market include the realisation of rising risk of infectious disease prevalence is expected to spur the industry statistics. Growing adoption of gene chips for pathogen detection in the field of forensics, nanotechnology and biodefense-related drug development will foster the market trends. Along with this increasing awareness regarding bioterrorism attacks in developed economies will significantly fuel the business outlook. Also rising R&D activities in the field of biotechnology and the availability of advanced biothreat detection devices, are set to enhance the market share. The emergence of COVID-19 boosts the demand for medical measures and threat detection procedures. Additionally, there is an increased production of vaccine and high demand for detection kits and quick diagnostics. The anthrax segment accounted for the largest market share in the Biodefense Market in Asia Pacific. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives in Asian countries, such as safe and security initiative, Special Measures Act for Pandemic preparedness, Civilian Protection Act and the Defense Research and Development Establishment (DRDE).
Impact of Covid-19
The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
Impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the global biodefense market during the forecast period, owing to the raising awareness between government agencies against bioterrorism or biological warfare amongst the consequences of COVID-19 pandemic. For instance, in April 2021, the Counter Terrorism Preparedness Network (CTPN) launched a detailed report titled ‘Bioterrorism: Applying the Lens of COVID-19’. The report's main goal was to discuss the threat of bioterrorism in the light of COVID-19 and the advancements in technology and biosciences. The report also suggested that it is essential that relevant industries makes recommendations to the government authorities to improve their preparedness and capabilities for bioterrorism and, as a result prepare them for public health crises. These factors are expected to support the growth of global biodefense market.
Highlighted with 32 tables and 40 figures, this 108-page report “Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
By Product type
• Vaccines
• Anthrax
• Smallpox
• Botulism
• Nuclear/Radiation
• E-Bola
• Zika
• Other Vaccines
• Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Samplers
• Identifiers
• Antibiotics
• Masks
• Other Products
By Sales Channel
• Online Sales
• Offline Sales
By Application
• Military
• Civilian
By Geography
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now